Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer
This article was originally published in The Pink Sheet Daily
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.
You may also be interested in...
At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.
It was an important week for Celgene, which made two cancer deals while producing data that help validate its $2.9 billion buyout of Abraxane.
VentiRx Pharmaceuticals Inc. has been working since 2007 to develop TLR8 agonists for allergic rhinitis and cancer, while considering how they might also be used in other indications. The company reported positive data from Phase I clinical trials in both areas within the past year, but has recently decided to move forward in cancer only.